Floatz logo

Treg Cells

Burkitt's Lymphoma

Masonic Cancer Center, University of MinnesotaCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

74 Active assets in the Burkitt's Lymphoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 4BBB
VINCRISTINE SULFATE
AIDS Malignancy Consortium
Phase 2BBB
VINDESINE
PETHEMA Foundation
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
AIDS Malignancy Consortium
Phase 4BBB

View all 50 →

Same molecule, other indications

Treg Cells is also rated in:

myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →